Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses

Nicola Abate, Alberico L. Catapano, Christie M. Ballantyne, Michael H. Davidson, Adam Polis, Steven S. Smugar, Andrew M. Tershakovec

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Patients with diabetes mellitus (DM) and metabolic syndrome (MS) are at increased risk of developing coronary heart disease. Objective: To compare the effects of ezetimibe/simvastatin (E/S) combination therapy, atorvastatin, and rosuvastatin in patients with DM, MS without DM, or neither disease. Methods: Subgroup analysis of data from two 6-week, randomized, double-blind trials comparing E/S 10/10, 10/20, 10/40, or 10/80 mg with either atorvastatin 10, 20, 40, or 80 mg (Study 1), or rosuvastatin 10, 20, or 40 mg (Study 2). Treatments were compared by pooling across all doses for effects on low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), non-HDL-C, apolipoprotein B (ApoB), LDL-C:HDL-C, TC:HDL-C, and LDL-C goal attainment. Results: E/S provided greater improvements than atorvastatin or rosuvastatin in LDL-C, TC, HDL-C (vs atorvastatin only), non-HDL-C, LDL-C:HDL-C, TC:HDL-C, and ApoB in all disease subgroups. There were no interactions of treatment by disease subgroup for these parameters, indicating a consistent treatment difference favoring E/S effect across the disease subgroups. A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. All treatments were well-tolerated, with generally similar adverse experience rates. Conclusions: Overall, E/S generally provided greater efficacy than either atorvastatin or rosuvastatin that was consistent across the subgroups of patients with DM, MS, or neither, in agreement with the results from the full study cohorts.

Original languageEnglish (US)
Pages (from-to)91-105
Number of pages15
JournalJournal of Clinical Lipidology
Volume2
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Simvastatin
LDL Cholesterol
HDL Cholesterol
Lipids
Cholesterol
Diabetes Mellitus
Apolipoproteins B
Therapeutics
S 10
Ezetimibe
Atorvastatin Calcium
Rosuvastatin Calcium
Coronary Disease
Cohort Studies
Education

Keywords

  • Atorvastatin
  • Cholesterol
  • Diabetes
  • Ezetimibe-simvastatin combination
  • Lipids
  • Metabolic syndrome
  • Rosuvastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither : Results of two subgroup analyses. / Abate, Nicola; Catapano, Alberico L.; Ballantyne, Christie M.; Davidson, Michael H.; Polis, Adam; Smugar, Steven S.; Tershakovec, Andrew M.

In: Journal of Clinical Lipidology, Vol. 2, No. 2, 04.2008, p. 91-105.

Research output: Contribution to journalArticle

Abate, Nicola ; Catapano, Alberico L. ; Ballantyne, Christie M. ; Davidson, Michael H. ; Polis, Adam ; Smugar, Steven S. ; Tershakovec, Andrew M. / Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither : Results of two subgroup analyses. In: Journal of Clinical Lipidology. 2008 ; Vol. 2, No. 2. pp. 91-105.
@article{b2e2295ca2f445f38b1bad8514382335,
title = "Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses",
abstract = "Background: Patients with diabetes mellitus (DM) and metabolic syndrome (MS) are at increased risk of developing coronary heart disease. Objective: To compare the effects of ezetimibe/simvastatin (E/S) combination therapy, atorvastatin, and rosuvastatin in patients with DM, MS without DM, or neither disease. Methods: Subgroup analysis of data from two 6-week, randomized, double-blind trials comparing E/S 10/10, 10/20, 10/40, or 10/80 mg with either atorvastatin 10, 20, 40, or 80 mg (Study 1), or rosuvastatin 10, 20, or 40 mg (Study 2). Treatments were compared by pooling across all doses for effects on low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), non-HDL-C, apolipoprotein B (ApoB), LDL-C:HDL-C, TC:HDL-C, and LDL-C goal attainment. Results: E/S provided greater improvements than atorvastatin or rosuvastatin in LDL-C, TC, HDL-C (vs atorvastatin only), non-HDL-C, LDL-C:HDL-C, TC:HDL-C, and ApoB in all disease subgroups. There were no interactions of treatment by disease subgroup for these parameters, indicating a consistent treatment difference favoring E/S effect across the disease subgroups. A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. All treatments were well-tolerated, with generally similar adverse experience rates. Conclusions: Overall, E/S generally provided greater efficacy than either atorvastatin or rosuvastatin that was consistent across the subgroups of patients with DM, MS, or neither, in agreement with the results from the full study cohorts.",
keywords = "Atorvastatin, Cholesterol, Diabetes, Ezetimibe-simvastatin combination, Lipids, Metabolic syndrome, Rosuvastatin",
author = "Nicola Abate and Catapano, {Alberico L.} and Ballantyne, {Christie M.} and Davidson, {Michael H.} and Adam Polis and Smugar, {Steven S.} and Tershakovec, {Andrew M.}",
year = "2008",
month = "4",
doi = "10.1016/j.jacl.2008.02.002",
language = "English (US)",
volume = "2",
pages = "91--105",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither

T2 - Results of two subgroup analyses

AU - Abate, Nicola

AU - Catapano, Alberico L.

AU - Ballantyne, Christie M.

AU - Davidson, Michael H.

AU - Polis, Adam

AU - Smugar, Steven S.

AU - Tershakovec, Andrew M.

PY - 2008/4

Y1 - 2008/4

N2 - Background: Patients with diabetes mellitus (DM) and metabolic syndrome (MS) are at increased risk of developing coronary heart disease. Objective: To compare the effects of ezetimibe/simvastatin (E/S) combination therapy, atorvastatin, and rosuvastatin in patients with DM, MS without DM, or neither disease. Methods: Subgroup analysis of data from two 6-week, randomized, double-blind trials comparing E/S 10/10, 10/20, 10/40, or 10/80 mg with either atorvastatin 10, 20, 40, or 80 mg (Study 1), or rosuvastatin 10, 20, or 40 mg (Study 2). Treatments were compared by pooling across all doses for effects on low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), non-HDL-C, apolipoprotein B (ApoB), LDL-C:HDL-C, TC:HDL-C, and LDL-C goal attainment. Results: E/S provided greater improvements than atorvastatin or rosuvastatin in LDL-C, TC, HDL-C (vs atorvastatin only), non-HDL-C, LDL-C:HDL-C, TC:HDL-C, and ApoB in all disease subgroups. There were no interactions of treatment by disease subgroup for these parameters, indicating a consistent treatment difference favoring E/S effect across the disease subgroups. A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. All treatments were well-tolerated, with generally similar adverse experience rates. Conclusions: Overall, E/S generally provided greater efficacy than either atorvastatin or rosuvastatin that was consistent across the subgroups of patients with DM, MS, or neither, in agreement with the results from the full study cohorts.

AB - Background: Patients with diabetes mellitus (DM) and metabolic syndrome (MS) are at increased risk of developing coronary heart disease. Objective: To compare the effects of ezetimibe/simvastatin (E/S) combination therapy, atorvastatin, and rosuvastatin in patients with DM, MS without DM, or neither disease. Methods: Subgroup analysis of data from two 6-week, randomized, double-blind trials comparing E/S 10/10, 10/20, 10/40, or 10/80 mg with either atorvastatin 10, 20, 40, or 80 mg (Study 1), or rosuvastatin 10, 20, or 40 mg (Study 2). Treatments were compared by pooling across all doses for effects on low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), non-HDL-C, apolipoprotein B (ApoB), LDL-C:HDL-C, TC:HDL-C, and LDL-C goal attainment. Results: E/S provided greater improvements than atorvastatin or rosuvastatin in LDL-C, TC, HDL-C (vs atorvastatin only), non-HDL-C, LDL-C:HDL-C, TC:HDL-C, and ApoB in all disease subgroups. There were no interactions of treatment by disease subgroup for these parameters, indicating a consistent treatment difference favoring E/S effect across the disease subgroups. A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. All treatments were well-tolerated, with generally similar adverse experience rates. Conclusions: Overall, E/S generally provided greater efficacy than either atorvastatin or rosuvastatin that was consistent across the subgroups of patients with DM, MS, or neither, in agreement with the results from the full study cohorts.

KW - Atorvastatin

KW - Cholesterol

KW - Diabetes

KW - Ezetimibe-simvastatin combination

KW - Lipids

KW - Metabolic syndrome

KW - Rosuvastatin

UR - http://www.scopus.com/inward/record.url?scp=40649126974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40649126974&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2008.02.002

DO - 10.1016/j.jacl.2008.02.002

M3 - Article

C2 - 21291725

AN - SCOPUS:40649126974

VL - 2

SP - 91

EP - 105

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 2

ER -